Some of the names on the move ahead of the open.» Read More
Bristol-Myers Squibb and Merck stocks climbed higher Monday as analysts said billions stood to be made from treatment breakthroughs.
Take a look at some of Monday's midday movers:
A dispute within the FDA on whether to put new lung-cancer warnings on ARBs taken by millions of people is unlikely to have any significant effect on the manufacturers stocks.
Several key areas are dangerous for investors in this economic environment, said Jim Cramer, and his charitable trust sold two key stocks.
The spotlight at this year's American Society of Clinical Oncologists meeting will be on data from Bristol-Myers Squibb, Roche, and Merck on a new class of cancer drugs.
Stocks closed down 1 percent after the minutes from the last Fed policy setting meeting suggested the central bank could begin tapering bond purchases sooner than the market expects.
The ASCO meeting scheduled to begin on May 31st could generate a cornucopia of health care catalysts, said Jim Cramer.
Take a look at some of Wednesday midday movers:
Patent expirations on big-name drugs has resulted in modestly less spending on medicines in the U.S. for the first time in at least 55 years, a report showed Thursday.
A pullback would be healthy for the stock market — and may be overdue, Josh Brown says.
U.S. stock index futures were higher Thursday, lifted by a batch of better-than-expected earnings and after an upbeat jobless claims report.
Pockets of weakness in the market have captured Cramer's attention. Is the selling really warranted?
Big pharma is abandoning antibiotic research at a time when fears over superbugs are growing at an alarming rate, leaving smaller firms to fill the breach.
It's make-or-break time for the first-quarter earnings season, and it comes just as the stock market is showing signs of strain.
The "Talking Squawk" blog is meant to be a funny, sarcastic look at business news through the unique "Squawk Box" lens. But it was difficult to think about anything from that viewpoint this week.
Johnson & Johnson is giving biotech start-ups space on the cheap, hoping if a company creates a hot new drug, they'll remember J&J.
As some on Wall Street worry about a stock market bubble, Jim Cramer looks at just how frothy stocks are.
Investors are too focused on the Federal Reserve and it's costing them, since other factors are more important for stocks, said Cramer.
While the other big pharma stocks roared, Cramer said one was left behind.
Don't hate on the market, Chris Verrone of Strategas says.